- Home
- Publications
- Publication Search
- Publication Details
Title
CS1-Directed Monoclonal Antibody Therapy for Multiple Myeloma
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 30, Issue 16, Pages 2013-2015
Publisher
American Society of Clinical Oncology (ASCO)
Online
2012-05-01
DOI
10.1200/jco.2011.40.4061
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The effect of elotuzumab on natural killer (NK) cell function against multiple myeloma (MM).
- (2017) S. M. Collins et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
- (2012) Andrzej J. Jakubowiak et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
- (2011) D. M. Benson et al. BLOOD
- Monoclonal antibodies in the treatment of multiple myeloma
- (2011) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Differential effects of IL-2 and IL-21 on expansion of the CD4+CD25+Foxp3+T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia
- (2010) Aruna Gowda et al. mAbs
- Monoclonal antibodies for cancer immunotherapy
- (2009) Louis M Weiner et al. LANCET
- Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
- (2009) F. van Rhee et al. MOLECULAR CANCER THERAPEUTICS
- Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function
- (2009) Mario-Ernesto Cruz-Munoz et al. NATURE IMMUNOLOGY
- Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
- (2008) R. Lapalombella et al. BLOOD
- The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
- (2008) Christine Galustian et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
- (2008) L. Wu et al. CLINICAL CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started